載入中
Picard Medical, Inc., through its associated companies, is dedicated to the entire process of medical device commercialization, from initial design and manufacturing to production, distribution, marketing, and sales. A key product in its portfolio is the SynCardia TAH, a sophisticated total artificial heart specifically engineered to supplant a failing human heart in individuals afflicted with advanced cardiac disease. The firm's market presence extends across the United States, Europe, and other international regions. Established in 2021, Picard Medical maintains its primary operations in Tucson, Arizona, functioning as a direct subsidiary of Hunniwell Picard I, Llc.
前收盤價
US$6.93
+US$1.15 · +19.90%
盤前
US$6.70
−US$0.23 · -3.32%
10月6日 上午8:13 ET
盤中時間採用ET。市場資料可能有所延遲。
Picard Medical, Inc., through its associated companies, is dedicated to the entire process of medical device commercialization, from initial design and manufacturing to production, distribution, marketing, and sales. A key product in its portfolio is the SynCardia TAH, a sophisticated total artificial heart specifically engineered to supplant a failing human heart in individuals afflicted with advanced cardiac disease. The firm's market presence extends across the United States, Europe, and other international regions. Established in 2021, Picard Medical maintains its primary operations in Tucson, Arizona, functioning as a direct subsidiary of Hunniwell Picard I, Llc.
日內區間
目前US$6.93
52週區間
目前US$6.93
盤中時間採用ET。市場資料可能有所延遲。
Picard Medical, Inc., through its associated companies, is dedicated to the entire process of medical device commercialization, from initial design and manufacturing to production, distribution, marketing, and sales. A key product in its portfolio is the SynCardia TAH, a sophisticated total artificial heart specifically engineered to supplant a failing human heart in individuals afflicted with advanced cardiac disease. The firm's market presence extends across the United States, Europe, and other international regions. Established in 2021, Picard Medical maintains its primary operations in Tucson, Arizona, functioning as a direct subsidiary of Hunniwell Picard I, Llc.
日內區間
目前US$6.93
52週區間
目前US$6.93
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|
| 營收 | 494萬 USD | 439.1萬 USD | 504.3萬 USD | 411.3萬 USD |
| 銷貨成本 | 474萬 USD | 450.3萬 USD | 735.4萬 USD | 910.1萬 USD |
| 毛利 | 20萬 USD | −11.2萬 USD | −231.1萬 USD | −498.8萬 USD |
| 研究與開發 | 300萬 USD | 338萬 USD | 221.3萬 USD | 190.2萬 USD |
| 銷售、一般及管理費用 | 1000萬 USD | 1022萬 USD | 1097.8萬 USD | 417.7萬 USD |
| 營業費用 | 1300萬 USD | 1360萬 USD | 1319.1萬 USD | 607.9萬 USD |
| 利息收入 | — | — | 2000 USD | 9000 USD |
| 利息支出 | — | 306.7萬 USD | 14萬 USD | 5000 USD |
| 折舊和攤銷 | 51.2萬 USD | 54.3萬 USD | 58.5萬 USD | 54.5萬 USD |
| 營業利益 | −1280萬 USD | −1371.2萬 USD | −1550.2萬 USD | −1106.7萬 USD |
| 淨利 | −2700萬 USD | −2105.5萬 USD | −1556.9萬 USD | −1116.8萬 USD |
公司資料更新於 2026年10月6日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
